本文選題：丙型病毒性肝炎 + DAA�。� 參考：《南昌大學(xué)》2017年碩士論文

【摘要】：背景:我國(guó)是肝病大國(guó),丙型肝炎病毒(Hepatitis C virus,HCV)的感染率一直居高不下,然而公眾對(duì)于慢性丙型肝炎(Chronic hepatitis C,CHC)的了解一直處于較低的水平。慢性丙型肝炎的起病隱匿及臨床癥狀的不明顯,導(dǎo)致HCV感染者診斷和治療可及性較低。長(zhǎng)期慢性的HCV感染會(huì)對(duì)肝臟功能造成嚴(yán)重的損害,甚至引起肝硬化(liver cirrhosis,LC)、肝細(xì)胞癌(Hepatocellular Carcinoma,HCC)和肝功能衰竭。據(jù)WHO報(bào)道,全球約有1.3億至1.5億人受到慢性HCV感染,在未來(lái)5-10年間,HCV相關(guān)的肝臟疾病仍將會(huì)持續(xù)增加。傳統(tǒng)HCV感染患者治療方案病毒持續(xù)應(yīng)答率(Sustained virological response,SVR)較低,副作用大,治療效果差。自2011年直接抗病毒藥物(Direct acting antivirals agent,DAA)問(wèn)世以來(lái),丙型病毒性肝炎治療取得了飛速發(fā)展,同時(shí)對(duì)于丙型病毒性肝炎直接抗病毒藥物各方面的研究也越來(lái)越多。目的:通過(guò)綜述直接抗病毒藥物治療慢性丙型病毒性肝炎的研究現(xiàn)狀,從而為臨床上治療丙型病毒性肝炎提供一定的參考。方法:以“丙型病毒性肝炎、DAA、直接抗病毒藥物、耐藥性、肝硬化”等關(guān)鍵詞進(jìn)行檢索,找出丙肝直接抗病毒藥物的相關(guān)研究并對(duì)其分類、治療效果及安全性等進(jìn)行總結(jié)。結(jié)果與結(jié)論:近年來(lái)有大量關(guān)于慢性丙型病毒性肝炎直接抗病毒藥物(DAA)研究的文獻(xiàn),綜合這些研究結(jié)果表明,DAA作為新一代抗HCV病毒藥物,具有獲得持續(xù)病毒學(xué)應(yīng)答率(SVR)高、復(fù)發(fā)率低、不良反應(yīng)少等優(yōu)勢(shì),且DAA在HCV相關(guān)肝硬化患者的治療中具有極為廣闊的應(yīng)用前景。但DAA單藥治療HCV感染易產(chǎn)生耐藥性,指南[1]推薦不同靶點(diǎn)的藥物需同時(shí)使用。
[Abstract]:Background: China is a large liver disease country, the infection rate of hepatitis C virus (hepatitis C virus) has been high, but the public understanding of chronic hepatitis C virus (Chronic hepatitis) has been at a low level. The occult onset of chronic hepatitis C and the lack of clinical symptoms lead to the low availability of diagnosis and treatment in patients with HCV. Chronic HCV infection can cause serious damage to liver function, and even lead to liver cirrhosis, hepatocellular carcinoma (HCC) and liver failure. According to the WHO, about 130 million to 150 million people worldwide are infected with chronic HCV, and the number of HCV-related liver diseases will continue to increase in the next five to 10 years. The rate of sustained virological response in patients with traditional HCV infection was low, the side effect was large, and the therapeutic effect was poor. Since the direct antiviral drug Direct acting antivirals agentaday (DAA) came out in 2011, the treatment of viral hepatitis C has made rapid progress. At the same time, there are more and more researches on all aspects of direct antiviral drugs for viral hepatitis C. Objective: to review the research status of direct antiviral drugs in the treatment of chronic hepatitis C, and to provide some references for clinical treatment of viral hepatitis C. Methods: the key words of "DAA, direct antiviral drug, drug resistance, liver cirrhosis" were searched to find out the related research of direct antiviral drugs in hepatitis C and to summarize their classification, therapeutic effect and safety. Results & conclusion: in recent years, there have been a large number of literatures on direct antiviral drugs (DAA) in chronic hepatitis C. synthesizing these results indicate that as a new generation of antiviral drugs, it has a high rate of obtaining persistent virological response. The recurrence rate is low, the adverse reaction is less, and DAA has a broad application prospect in the treatment of HCV related cirrhosis patients. However, DAA monotherapy is susceptible to drug resistance in the treatment of HCV infection, and guidelines [1] recommend that different target drugs should be used at the same time.
【學(xué)位授予單位】：南昌大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R512.63

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 ;美國(guó)警示直接抗丙肝病毒藥物的乙肝復(fù)燃風(fēng)險(xiǎn)[J];中國(guó)藥物評(píng)價(jià);2016年06期

2 溫曉玉;�？∑�;;直接抗病毒藥物治療慢性丙型肝炎的作用機(jī)制[J];臨床肝膽病雜志;2016年09期

3 Conti F;劉苗霞;溫曉玉;;直接抗病毒藥物治療的丙型肝炎肝硬化患者肝癌的早期發(fā)生和復(fù)發(fā)情況[J];臨床肝膽病雜志;2016年09期

4 卞丹丹;鄭素軍;;丙型肝炎治療的DAA時(shí)代[J];肝博士;2016年03期

5 安子英;盛秋菊;張，

本文編號(hào)：1915629